NIH R01 · 2024
Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemia
Acute myeloid leukemia (AML) is a disease of blocked differentiation in which blasts fail to mature and proliferate continuously. Differentiation therapy, which aims to reactivate latent maturation programs and induce cell cycle exit, is curative in the promyelocytic (APL) AML subtype, but not in other AML subtypes. Epigenetic factors help sustain the differentiation block, and inhibitors of regulators such as the LSD1, BRD4, and DOT1L has recently been shown to re-activate myeloid differentiation programs in selected AML models. However, these inhibitors generally do not achieve terminal differentiation and disease remission. Accordingly, there is significant need to identify more…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.